Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01326104 · ClinicalTrials.gov registry record · Phase 2
Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor
A Phase 2 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT01326104 is a Phase 2 study that has completed, run by University of Florida. The registered enrollment target is 26 participants.
The verdict
NCT01326104, a Phase 2 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
Immunotherapy is a specific approach to treating cancer that has shown promise in adult patients for the treatment of melanoma, malignant brain tumors, and other cancers. The study investigators will use the experience they have gained from these studies to try to improve the outcome for children affected by a recurrent brain tumor. Approximately 35 patients with first recurrence of medulloblastoma (reMB)/supratentorial primitive neuroectodermal tumors (PNETs) will be treated with tumor-specific immune cells and dendritic cell vaccines to see what impact they have on the tumor.
Interventions
- BIOLOGICAL TTRNA-xALT
- BIOLOGICAL TTRNA-DCs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2010-09-07 |
| Est. Completion | 2025-03-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01326104
The ClinicalTrials.gov registry entry for NCT01326104 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TTRNA-xALT is the first listed.
NCT01326104 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01326104 about?
NCT01326104 is a clinical study titled "Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor". Immunotherapy is a specific approach to treating cancer that has shown promise in adult patients for the treatment of melanoma, malignant brain tumors, and other cancers. The study investigators will use the experience they have gained from these studies to try to improve the outcome for children af...
What is the current status of trial NCT01326104?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2010-09-07. Estimated completion is 2025-03-28.
What interventions are being tested in trial NCT01326104?
The interventions under investigation include: TTRNA-xALT (BIOLOGICAL), TTRNA-DCs (BIOLOGICAL).
Who is sponsoring clinical trial NCT01326104?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.